Prosecution Insights
Last updated: October 02, 2026

Examiner: RILEY, JEZIA

Tech Center 1600 • Art Units: 1637 1651 1681 1682

This examiner grants 83% of resolved cases

Analysis

Jezia Riley is an examiner in Tech Center 1600 and Art Unit 1637. She has a high volume of 1319 resolved cases. Her allowance rate is 82.9 percent. The interview lift is 7.3 percent, indicating that interviews provide a modest benefit to the already high probability of allowance. The median days to allowance is 894, which is quite fast for Tech Center 1600.

With 1319 resolved cases, these metrics are highly reliable. The 82.9 percent allowance rate suggests a favorable environment for applicants. The 894 median days indicate that prosecution moves quickly through this art unit. The 1319 resolved cases represent one of the largest data sets in the center. The 7.3 percent lift suggests that while not always necessary, interviews still offer a positive impact.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

82.9%
Allow Rate
+22.9% vs TC avg
1,334
Total Applications
+7.3%
Interview Lift
894
Avg Prosecution Days
Based on 1319 resolved cases, 2023–2026

Rejection Statute Breakdown

2.5%
§101 Eligibility
24.8%
§102 Novelty
26.6%
§103 Obviousness
21.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18561834 METHODS FOR COMPLEMENT STRAND SEQUENCING Non-Final OA Oxford Nanopore Technologies PLC
18488502 MOLECULES COMPRISING BRANCHED LINKERS AND METHODS OF USE Non-Final OA 10x Genomics, Inc.
18680822 SYNTHESIS AND PREPARATION OF ULTRA-LOW VISCOSITY AND HIGH MAGNETIC SUSCEPTIBILITY MAGNETIC IONIC LIQUIDS Non-Final OA Iowa State University Research Foundation, Inc.
18687723 HYBRIDIZATION PROBES CONTAINING FLUORINATED CARBON CHAINS AND RELATED METHODS Non-Final OA University of Utah Research Foundation
18800335 SYNTHESIS OF BACKBONE MODIFIED MORPHOLINO OLIGONUCLEOTIDES AND CHIMERAS USING PHOSPHORAMIDITE CHEMISTRY Non-Final OA THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate
18009111 NUCLEIC ACID LIPID PARTICLE VACCINE Non-Final OA THE UNIVERSITY OF TOKYO
18718194 METHOD FOR DETECTING MUTATIONS IN TARGET BASE SEQUENCE OF NUCLEIC ACID, METHOD FOR SELECTIVELY INHIBITING AMPLIFICATION OF NUCLEIC ACID, AND KIT FOR IMPLEMENTING SAME Non-Final OA NITTO BOSEKI CO., LTD.
18715009 AGENT FOR RAISING MELTING TEMPERATURE OF DOUBLE-STRANDED NUCLEIC ACID, AND USES THEREFOR Non-Final OA NITTO BOSEKI CO., LTD.
18691513 ZWITTERIONIC SURFACES FOR LOCALIZED SURFACE PLASMON RESONANCE Non-Final OA THE TRUSTEES OF INDIANA UNIVERSITY
18650800 CONTROLLED POLYNUCLEOTIDE TRANSLOCATION IN NANOPORE SEQUENCING Non-Final OA ILLUMINA, INC.
18393291 METHODS OF SEQUENCING USING 3' BLOCKED NUCLEOTIDES Non-Final OA Illumina, Inc.
18569532 METHODS OF DETECTING METHYLCYTOSINE AND HYDROXYMETHYLCYTOSINE BY SEQUENCING Non-Final OA Illumina, Inc.
18176918 NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF Non-Final OA Promega Corporation

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month